TFA
SGMT icon

Toth Financial Advisory’s Sagimet Biosciences SGMT Stock Holding History

Toth Financial Advisory’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-650
Closed -$3.85K – 1013
2025
Q4 		$3.85K Hold
650
– – ﹤0.01% 656
2025
Q3 		$4.46K Hold
650
– – ﹤0.01% 624
2025
Q2 		$4.95K Buy
+650
New +$2.74K ﹤0.01% 559
2024
Q3 		– Sell
-90
Closed -$308 – 766
2024
Q2 		$308 Hold
90
– – ﹤0.01% 727
2024
Q1 		$488 Buy
+90
New +$646 ﹤0.01% 700

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Toth Financial Advisory's SGMT Position: Q1 2026 in Review

Toth Financial Advisory sold out of Sagimet Biosciences (SGMT) in Q1 2026, closing a stake of 650 shares — an estimated $3.85K sold.

Toth Financial Advisory first reported a position in SGMT in Q1 2024 and held it in 5 quarters. The position peaked at $4.95K in Q2 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Toth Financial Advisory reported no remaining Sagimet Biosciences position as of Q1 2026 after selling out during the quarter.
  • Toth Financial Advisory sold 650 Sagimet Biosciences shares in Q1 2026, an estimated $3.85K.
  • Toth Financial Advisory first reported a position in Sagimet Biosciences in Q1 2024 and held it in 5 quarters.
  • Toth Financial Advisory's Sagimet Biosciences position peaked at $4.95K in Q2 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Toth Financial Advisory's 13F filing for Q1 2026, filed 16 Apr 2026.